Article Text

Download PDFPDF
Financial toxicity in ovarian cancer
  1. Allison L Swiecki-Sikora1,
  2. Amaranta D Craig2 and
  3. Christina S Chu2
  1. 1Department of Obstetrics, Gynecology and Reproductive Sciences, Temple University Hospital, Philadelphia, Pennsylvania, USA
  2. 2Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
  1. Correspondence to Dr Allison L Swiecki-Sikora, Dept. of Obstetrics, Gynecology and Reproductive Sciences, Temple University Hospital, Philadelphia, Pennsylvania, USA; allison.swiecki-sikora2{at}tuhs.temple.edu

Abstract

Ovarian cancer is the most costly and deadly of the gynecologic malignancies. Financial toxicity from out-of-pocket costs for direct care and medications as well as indirect costs from lost income is a growing challenge in oncology. The aim of this review is to focus on recent financial toxicity literature in the gynecologic oncology sphere and highlight specific issues and challenges regarding financial toxicity in ovarian cancer. Treatment options for ovarian cancer lead to variable costs for patients, and there are risk factors for high financial toxicity unique to gynecologic oncology patients. Identification and prompt intervention for those most at risk can help alleviate financial distress from ovarian cancer care.

  • financial toxicity
  • ovarian cancer
  • health disparities

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Twitter @amarantac

  • Contributors ALS-S: conceptualization, research, writing (original and editing). ADC: editing. CSC: conceptualization and editing.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.